Chromosome 21 gain is dispensable for transient myeloproliferative disorder driven by a novel GATA1 mutation

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome

(2019) Maurice Labuhn et al.   CANCER CELL

GATA1s exerts developmental stage-specific effects in human hematopoiesis

(2018) Sofia Gialesaki et al.   HAEMATOLOGICA

GATA1s exerts developmental stage-specific effects in human hematopoiesis

(2018) Sofia Gialesaki et al.   HAEMATOLOGICA

Systematic Cellular Disease Models Reveal Synergistic Interaction of Trisomy 21 and GATA1 Mutations in Hematopoietic Abnormalities

(2016) Kimihiko Banno et al.   Cell Reports

Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases

(2013) Angela V Toms et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Janus Kinase Deregulation in Leukemia and Lymphoma

(2012) Edwin Chen et al.   IMMUNITY

The GATA1s isoform is normally down-regulated during terminal haematopoietic differentiation and over-expression leads to failure to repress MYB, CCND2 and SKI during erythroid differentiation of K562 cells

(2012) Christina Halsey et al.   Journal of Hematology & Oncology

miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia

(2010) J.-H. Klusmann et al.   GENES & DEVELOPMENT

Trisomy 21 enhances human fetal erythro-megakaryocytic development

(2008) S. T. Chou et al.   BLOOD

Treatment and prognostic impact of transient leukemia in neonates with Down syndrome

(2008) J.-H. Klusmann et al.   BLOOD